ArticleWorld journal of clinical oncology2025
Immunotherapy in gastrointestinal stromal tumors: Current landscape and future horizons.
Article in World journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Non-Coding RNAs in Gastrointestinal Stromal Tumors: Regulatory Networks, Drug Resistance, and Clinical Implications.International journal of molecular sciences · 2026Review
- Immune Microenvironment Dynamics and Therapeutic Targets in GIST Revealed by Multi-Omics and Functional Validation.Journal of cellular and molecular medicine · 2026Article
- Tumor-Restricted CXCR4 and MIF Signaling Axis is Associated with T Cell-Mediated Macrophage Exclusion in Gastrointestinal Stromal Tumors.International journal of general medicine · 2026Article
- Enhanced formation of tertiary lymphoid structures shapes the anti-tumor microenvironment in gastrointestinal stromal tumors after imatinib targeted therapy.Theranostics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal stromal tumors (GISTs) feature a unique tumor microenvironment (TME) with abundant immune infiltrates, including CD8+ T cells and tertiary lymphoid structures, alongside significant immune escape mechanisms such as indoleamine 2,3-dioxygenase (IDO) overexpression, MHC I loss, and regulatory T-cell activity. These factors contribute to an immunosuppressive TME, limiting the effectiveness of immune responses. Recent proteomic and immune profiling has identified distinct immune clusters, ranging from highly infiltrated "hot" tumors to immune-desert "cold" tumors, offering new insights into immune heterogeneity and prognostic stratification. While tyrosine kinase inhibitors (TKIs) like imatinib have shown immunomodulatory effects, clinical trials with immune checkpoint inhibitors (ICIs) alone or in combination have yielded modest outcomes. This editorial examines the immunologic landscape of GIST, explores the interplay between ICIs and TKIs, and highlights emerging therapeutic strategies such as IDO inhibition, bispecific antibodies, and patient selection based on TME characteristics. These insights pave the way for more effective immunotherapy approaches in GIST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.